The Top 10 World's Leading Pharmaceutical Companies: Merck

Table of Contents

WORLDWIDE MARKET DYNAMICS AND TRENDS

COMPANY STRATEGIC ASSESSMENTS

• Merck

SECTION I: EXECUTIVE SUMMARY

• A 5-10 page synopsis of key sections.

SECTION II: BUSINESS ORGANIZATION

• History of the company' s pharmaceutical business evolution, which is important to understanding the corporate culture, management mentality, and strategies.
• Most recent M&A activity and significant organizational changes.
• Current organizational structure.

SECTION III: SENIOR MANAGEMENT

• Names, titles, and background of senior managers.

SECTION IV: FACILITIES AND EMPLOYEES

• Major administrative, manufacturing, and R&D facilities in the U.S. and abroad.
• Manufacturing practices.
• New plants under construction.
• U.S. and international work force size and distribution.

SECTION V:TECHNOLOGICAL KNOW-HOW

• Internally developed and acquired technologies, processes, and related capabilities.
• Know-how in biotechnology and other pertinent fields.
• Proprietary technologies and patent litigations.

SECTION VI: PRODUCT PORTFOLIO ANALYSIS

• Extensive review of major ethical, OTC, and generic drugs.
• Most recent new drug introductions and indications.

SECTION VII: MARKETING TACTICS

• Sales force size and structure in the U.S., Europe, Japan, and other regions.
• Major sales office locations.

SECTION VII: MARKETING TACTICS

• Sales force in the U.S., Europe, and other regions.
• Distribution strategies.
• Major promotional tactics.

SECTION VIII: FINANCIAL ANALYSIS

• The U.S. and international sales and operating profit estimates by division, geographic region, therapeutic category, and individual drug.
• The five-year sales and operating profit performance.

SECTION IX: R&D EXPENDITURES AND MAJOR PROGRAMS

• The R&D budget.
• Research facilities and staff.
• New technologies, drugs, and indications in development, including their phase and anticipated introduction dates.

SECTION X: COLLABORATIVE ARRANGEMENTS

• Major joint venture, distribution, OEM, and licensing partners, both industrial and academic.
• Terms of collaborative agreements and specific products involved.

SECTION XI: STRATEGIC DIRECTION

• Major strengths and weaknesses.
• Business, new product development, and marketing objectives and strategies.
• Anticipated acquisitions, joint ventures, and divestitures.
• Worldwide sales force size.

COMPARATIVE ANALYSIS

In this section of the report, the Top 10 companies are ranked according to the following criteria:

• Worldwide sales and rank products.
• Operating profit and margins.
• R&D expenditures.